{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-099123","form_type":"8-K","ticker":"KR","cik":"0000056873","company_name":"KROGER CO","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.391793+00:00","generated_at":"2026-06-10T22:24:02.485046+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kroger Q2 adj EPS $0.96, $1.4B opioid charge, $1.9B C&S divestiture","bullets":["Q2 sales $33.9B (-2% YoY); ID sales +1.0%; operating loss ($479M) incl $1.4B opioid charge; adj EPS $0.96 vs $0.90 last year.","Opioid settlement: up to $1.2B to states/subdivisions, $36M to tribes over 11 yrs, $177M fees; after-tax NPV ~$870M; charge in Q2.","Divestiture: definitive agreement with C&S for 413 stores, 8 DCs, 2 offices, 5 private labels; $1.9B cash; option for up to 237 more stores.","FY2023 guidance reaffirmed: adj EPS $4.45-$4.60, adj FIFO operating profit $5.0-$5.2B, capex $3.4-$3.6B.","Net total debt to adj EBITDA ratio 1.31 (target 2.30-2.50); merger on track for early 2024 subject to FTC clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-099123","json":"https://secwatch.observer/filing/0001104659-23-099123.json","markdown":"https://secwatch.observer/filing/0001104659-23-099123.md","text":"https://secwatch.observer/filing/0001104659-23-099123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/56873/000110465923099123/0001104659-23-099123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/56873/000110465923099123/tm2325655d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:24:02.485046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20fa1030b8797f5f20cb90e922120204d4b1f13d","claim":"KROGER CO reported second quarter 2023 results: revenue $33.9 billion, EPS $(0.25). Guidance reaffirmed.","evidence_excerpt":"on operating profit was slightly positive. ** Includes a $1.4 billion ($1.54 loss per share) charge related to nationwide opioid settlement framework. Total company sales were $33.9 billion in the second quarter, compared to $34.6 billion for the same period last year. Excluding fuel, sales increased 1.1% compared to the same period last year. Gross margin was 21.8%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/56873/000110465923099123/0001104659-23-099123-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"$33.9 billion"},{"label":"EPS","value":"$(0.25)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}